Skip to content
Research Article Open access CC BY 3.0

Simple Reversed-Phase High Performance Liquid Chromatographic Estimation of the Antiretroviral Agent Efavirenz from Human Plasma

Benjamin U. Ebeshi, Oluseye O. Bolaji, Margaret Oluka, Vaikosen N. Edebi, Julius O. Soyinka, Anastasia Guantai

Journal of Pharmaceutical Research International · pp. 145–157 · Published 5 Oct 2013

10.9734/BJPR/2014/4123

Abstract

Aims: Sequel to the resurgence of TB co-infection in HIV/AIDS patients in sub-Saharan Africa, efavirenz has become an important component of the highly active antiretroviral treatment (HAART). The objective of this study therefore is to provide a simple reversed-phase high performance liquid chromatographic (HPLC) method for the determination of efavirenz in human plasma. Study Design: Method development and experimental study. Place and Duration of Study: School of Pharmacy, University of Nairobi, Nairobi, Kenya, between October 2009 and September 2010. Methodology: A 500µl drug-free plasma sample was each placed in six different centrifuge tubes (2ml) and varying aliquots of the stock solution (100μg/ml) of efavirenz were spiked and vortexed for 60sec to give concentrations of 0.5, 1.0, 2.0, 4.0, 8.0 and 16µg/ml for calibration standards and 2.0, 4.0, 8.0 and 16.0µg/ml for quality control samples. The off-column sample pretreatment was carried out by protein precipitation using ice-cold acetonitrile. The samples were chromatographed in a phenomenex (C18) 5µm particle size column with 250x4.6mm I.D and UV detection at 254nm using a mobile phase, which was made up of a mixture of solutions A and B. Both consisted of acetonitrile, 25mM ammonium acetate buffer and glacial acetic acid in proportions of 90:10:0.1 and 10:90:0.1(v/v), respectively. The analytical technique was validated for precision, accuracy and analyte recovery. Results: The calibration plot for efavirenz was found to be linear over the concentration range of 0.5 to 16.0µg/ml with the regression line equation obtained as y=26842x–409.4 and the regression coefficient (R2=0.999), which allows for accurate reading of the concentrations of the test samples. The RSD (%) in intraday and interday assays ranged from 0.44 to 0.78%. Accuracy ranged from 92 to 110% and the recovery was >97%. Conclusion: This new HPLC method is simple, reproducible and cost-effective and can be used for therapeutic drug monitoring of efavirenz in HIV/AIDS patients on HAART as demonstrated in this study.

Efavirenz HPLC pharmacokinetics plasma HIV/AIDS.

References (25)

  1. 1 Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [DOI]
  2. 2 Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism [DOI]
  3. 3 Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo [DOI]
  4. 4 From HIV to Tuberculosis and Back Again: A Tale of Activism in 2 Pandemics [DOI]
  5. 5 Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain [DOI]
  6. 6 Simultaneous Determination of the HIV Drugs Indinavir, Amprenavir, Saquinavir, Ritonavir, Lopinavir, Nelfinavir, the Nelfinavir Hydroxymetabolite M8, and Nevirapine in Human Plasma by Reversed-Phase High-Performance Liquid Chromatography [DOI]
  7. 7 Population pharmacokinetics of nevirapine in an unselected cohort of HIV‐1‐infected individuals [DOI]
  8. 8 Simple and rapid liquid chromatography method for determination of moxifloxacin in plasma [DOI]
  9. 9 Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection [DOI]
  10. 10 Establishment of a biobank and pharmacogenetics database of African populations [DOI]
  11. 11 Molecular Characterization of CYP2B6 Substrates [DOI]
  12. 12 Population pharmacokinetic meta-analysis with efavirenz [DOI]
  13. 13 High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid–liquid extraction [DOI]
  14. 14 High-Performance Liquid Chromatographic Method for the Simultaneous Determination of the Six HIV-Protease Inhibitors and Two Non-Nucleoside Reverse Transcriptase Inhibitors in Human Plasma [DOI]
  15. 15 Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals [DOI]
  16. 16 Plasma efavirenz concentrations and the association with CYP2B6 -516 G >T polymorphism in HIV-infected Thai children [DOI]
  17. 17 Conventional HPLC Method Used for Simultaneous Determination of the Seven HIV Protease Inhibitors and Nonnucleoside Reverse Transcription Inhibitor Efavirenz in Human Plasma [DOI]
  18. 18 Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography [DOI]
  19. 19 Substrates of Human Cytochromes P4S0 from Families CYP1 and CYP2: Analysis of Enzyme Selectivity and Metabolism [DOI]
  20. 20 Simultaneous Quantitative Assay of Atazanavir and 6 Other HIV Protease Inhibitors by Isocratic Reversed-Phase Liquid Chromatography in Human Plasma [DOI]
  21. 21 Efavirenz Plasma Concentrations and Cytochrome 2B6 Polymorphisms [DOI]
  22. 22 Simultaneous Determination of the Six HIV Protease Inhibitors (Amprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, and Saquinavir) Plus M8 Nelfinavir Metabolite and the Nonnucleoside Reverse Transcription Inhibitor Efavirenz in Human Plasma by Solid-Phase Extraction and Column Liquid Chromatography [DOI]
  23. 23 Simultaneous Quantitative Assay of Six HIV Protease Inhibitors, One Metabolite, And Two Non-Nucleoside Reverse Transcriptase Inhibitors in Human Plasma by Isocratic Reversed-Phase Liquid Chromatography [DOI]
  24. 24 Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography [DOI]
  25. 25 Sensitive and Rapid Method for the Simultaneous Quantification of the HIV-Protease Inhibitors Indinavir, Nelfinavir, Ritonavir, and Saquinavir in Human Plasma by Reversed-Phase Liquid Chromatography [DOI]

Cited by 4

The Cyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics

Samuel Bunu, Azibanasamesa Owaba, Edebi Vaikosen · Pharmacogenomics and Personalized Medicine · 2022

The association between cigarette smoking and efavirenz plasma concentration using the population pharmacokinetic approach

Ngah Kuan Chow, Sabariah Noor Harun, E‐Jinq Wong · British Journal of Clinical Pharmacology · 2021

Showing 2 of 4 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

40

Page views

0

PDF downloads

9

Outbound clicks

4

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.